Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aventis/Novartis update

This article was originally published in The Tan Sheet

Executive Summary

No formal negotiations have taken place on price tag for France's number one pharmaceutical company, Aventis CEO Igor Landau says in an April 2 conference call. Landau said the firm has "close to two months" to accelerate price negotiations if Novartis maintains interest; Aventis will propose resolutions including a 2003 dividend to shareholders at a May 19 annual meeting. If the merger is successful, Novartis likely would spin off non-core pharmaceutical and consumer brands into a separate entity (1"The Tan Sheet" March 29, 2004, p. 5)...

You may also be interested in...

Novartis/Aventis Consumer Products Combo Would Be Divested

Novartis would spin-off a combination of its consumer health products and Aventis' older drugs if the two companies were to merge

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts